New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
08:53 EDTSLXPSalix Xifaxan data should be positive, says JMP Securities
JMP Securities expects upcoming data for Salix's Xifaxan for the retreatment of diarrhea-predominant irritable bowel syndrome to be significantly positive. The firm expects the stock to rise significantly on the news. It reiterates a $150 price target and Outperform rating on the shares.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SLXP

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use